enVVeno Medical Corp (NVNO) Form 10-Q — Oct 29, 2026
enVVeno Medical filed its Q3 2026 10-Q reporting a Q3 net loss of $4.4 million, a slight improvement from $4.5 million a year ago, with nine-month losses narrowing 25% to $11.8 million on lower SG&A and VenoValve study costs. The company holds $18.5 million in cash and investments and guided that burn will rise to $4-5 million per quarter in H1 2027 as the TAVVE pivotal trial for the enVVe System launches — funding operations only into Q4 2027. With no revenue and an explicit need to raise additional capital, the equity story hinges on the FDA IDE-approved TAVVE study (10-patient safety stage starting Q4 2026, then 220 patients at up to 40 U.S.
Key figures
- Total Debt
- 0
- Total Assets
- 19489000
- Cash Position
- 2585000
- Shares Outstanding
- 694826
- Runway guidance
- sufficient cash and investments to fund operations into the fourth quarter of 2027
- Reverse split ratio
- 1:35 (effective January 20, 2026)
- Working capital usd
- 16400000
- Cash and investments usd
- 18500000
- Burn rate per quarter usd
- approximately $3-4 million, expected to rise to $4-5 million in H1 2027
- Rd expense nine months usd
- 7063000
- Sga expense nine months usd
- 5329000
- Atm proceeds nine months usd
- 313000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.